(2R)-2-amino-3-{[5-chloro-4-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,3,4-thiadiazol-2-yl)-2-fluorophenyl]oxy}propan-1-ol | 1246386-73-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: (2R)-2-amino-3-{[5-chloro-4-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,3,4-thiadiazol-2-yl)-2-fluorophenyl]oxy}propan-1-ol
• 英文别名: (2R)-2-amino-3-[5-chloro-4-[5-(3-chloro-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-2-fluorophenoxy]propan-1-ol
• CAS: 1246386-73-1
• 化学式: C₂₀H₂₀Cl₂FN₃O₃S
• 分子量: 472.368
• InChiKey: CRNGYYYGPGRTAC-GFCCVEGCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  30
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  119
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  (2R)-2-amino-3-{[5-chloro-4-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,3,4-thiadiazol-2-yl)-2-fluorophenyl]oxy}propan-1-ol 在 咪唑 、 四丁基氟化铵 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 26.0h， 生成 N-((R)-2-{5-chloro-4-[5-(3-chloro-4-isopropoxyphenyl)-[1,3,4]-thiadiazol-2-yl]-2-fluorophenoxy}-1-hydroxymethylethyl)formamide
  参考文献：
  名称：

  [EN] THIADIAZOLE MODULATORS OF S1P AND METHODS OF MAKING AND USING
  [FR] MODULATEURS THIADIAZOLE DE S1P ET PROCÉDÉS DE FABRICATION ET D'UTILISATION

  摘要：

  该发明涉及以下结构的化合物：其中这些变量在此有定义，以及制备和使用这些化合物作为S1P1和/或S1P5的激动剂的方法，例如用于治疗自身免疫疾病。

  公开号：

  WO2017004609A1

文献信息

• Modulators of S1P and Methods of Making And Using
  申请人：Bannen Lynne Canne

  公开号：US20100249071A1

  公开（公告）日：2010-09-30

  The invention is directed to Compounds of Formula I: as well as methods of making and using the compounds.

  本发明涉及式I的化合物，以及制备和使用该化合物的方法。
• [EN] MODULATORS OF S1P AND METHODS OF MAKING AND USING<br/>[FR] MODULATEURS DE S1P ET PROCÉDÉS DE RÉALISATION ET D'UTILISATION DE CEUX-CI
  申请人：EXELIXIS INC

  公开号：WO2010117662A1

  公开（公告）日：2010-10-14

  The invention is directed to Compounds of Formula (I): as well as methods of making and using the compounds.
• [EN] TERCYCLIC S1P3-SPARING, S1P1 RECEPTOR AGONISTS<br/>[FR] AGONISTES DE RÉCEPTEUR S1P1 ÉCONOMISANT LE S1P3 TERCYCLIQUE
  申请人：EXELIXIS INC

  公开号：WO2017004610A1

  公开（公告）日：2017-01-05

  Disclosed are tercyclic S1P3-sparing, S1P1 receptor agonists, as well as processes for making and methods of using the same. Poor solubility and cationic amphiphilic drug- likeness were liabilities identified for a lead series of S1P3-sparing, S1 P1 agonists originally developed from a high-throughput screening campaign. Subsequent optimization of these leads by balancing potency, selectivity, solubility and overall molecular charge. Focused SAR studies revealed favorable structural modifications that, when combined, produced compounds with overall balanced profiles. The low brain exposure observed in rat suggests that these compounds would be best suited for the potential treatment of peripheral autoimmune disorders.